<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[14, 27] chemo-nave patients with advanced non-small cell lung cancer.<br>[50, 61] chemo-nave non-small cell lung cancer patients.<br>[63, 76] Patients with chemo-nave stage IIIB/IV non-small cell lung cancer<br>[137, 142] A total of 80 patients<br></td>
<td width=33%>
[14, 27] chemo-nave patients with advanced non-small cell lung cancer.<br>[50, 61] chemo-nave non-small cell lung cancer patients.<br>[63, 76] Patients with chemo-nave stage IIIB/IV non-small cell lung cancer<br>[137, 148] A total of 80 patients were entered in this trial.<br></td>
<td width=33%>
[14, 27] chemo-nave patients with advanced non-small cell lung cancer.<br>[50, 62] chemo-nave non-small cell lung cancer patients.
<br>[63, 83] Patients with chemo-nave stage IIIB/IV non-small cell lung cancer were randomized into two treatment arms.<br>[137, 148] A total of 80 patients were entered in this trial.<br>[264, 272] advanced non-small cell lung cancer.<br></td>
</tr>
